FORTIS INC/ CA3495531079 /
| 2024-10-11 10:17:15 PM | Chg. +0.44 | Volume | Bid2024-10-11 | Ask2024-10-11 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 59.74CAD | +0.74% | 1.08 mill. Turnover: 64.17 mill. |
59.67Bid Size: 100 | 59.79Ask Size: 100 | 29.31 bill.CAD | 3.83% | 19.27 |
GlobeNewswire
08-06
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
07-23
Advisory: Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
07-02
Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
06-18
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program ...
GlobeNewswire
06-10
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
05-23
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire
05-15
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire
04-24
Advisory: Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold...
GlobeNewswire
04-24
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire
04-23
Maryland CareerQuest Connects Area Students with Training and Education Opportunities for Hands-On C...
GlobeNewswire
04-03
Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold Annual an...
GlobeNewswire
04-02
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire
03-28
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire
03-19
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
